Institut De Recherches Internationales Servier
Clinical trials sponsored by Institut De Recherches Internationales Servier, explained in plain language.
-
New hope for kids with rare epilepsy: first human trial launches
Disease control Recruiting nowThis study tests a new medicine, S230815, in children aged 2 to 12 with a rare genetic epilepsy called KCNT1-related developmental and epileptic encephalopathy. The goal is to see if the drug is safe and can help control seizures. The trial involves giving the drug via a spinal i…
Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 16, 2026 12:49 UTC
-
New pill targets hard-to-treat cancers with KRAS and BRAF mutations
Disease control Recruiting nowThis study tests an experimental oral drug, S241656, in people with advanced cancers (like lung, colon, or pancreatic) that have certain gene changes (KRAS, BRAF, or related). The drug is taken daily in 28-day cycles, either alone or with other cancer treatments. The goal is to f…
Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New hope for rare bone marrow cancer: targeted pill vs standard chemo
Disease control Recruiting nowThis study is for adults with a bone marrow disorder called MDS that has a specific gene change (IDH1 mutation) and who have not had a certain type of treatment before. The goal is to see if a daily pill (ivosidenib) works better than a standard injection (azacitidine) at control…
Phase: PHASE3 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 12, 2026 12:04 UTC